Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / MIR21



This biomarker is also known as:
  • hsa-mir-21,
  • MIRN21,
  • miRNA21,
  • miR-21,
  • mir-21,
  • microRNA 21,

View in BioMuta


From NCBI Gene: microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. miRNAs bind to complementary sequences in the 3' UTR of multiple target mRNAs, usually silencing the targeted mRNA. miRNAs may trigger the cleavage of their target molecules or act as translational repressors. miRNAs are thought to target approximatley 60% of all genes and are able to repress hundreds of targets each.


QA State: Curated
Type: Genomic
Short Name:
HGNC Name: MIR21


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Curated


MIR21 has been associated with many types of cancer, including lung, breast, pancreatic, and prostate.

Performance Comment

MIR21 is one of four members of a panel investigated as potential plasma biomarkers for non-small-cell lung cancer (NSCLC). The four members of the panel are MIR486-5p, MIR21, MIR126, MIR210.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

2016 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place March 14–15, 2016 in Bethesda, Maryland.

Announcement 11/05/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Monday-Tuesday, March 14-15, 2016, on the NCI campus. More information will be available later this autumn.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to /grants/guide/ pa-files/ PAR-15-289.html.